Based in Xiamen, Connecting with the World
With spring in full bloom, the 2026 China Association of Clinical Laboratory Practice Expo (CACLP) opened in Xiamen, bringing together professionals from the global laboratory medicine community.
At this year's exhibition, Medconn made a strong appearance with a more international vision, showcasing a portfolio of innovative diagnostic products and marking an important milestone with the global launch of its FDA-cleared HbA1c solutions—highlighting the growing capabilities of Chinese IVD innovation on the global stage.
Global Recognition — FDA Clearance Marks a New Milestone
One of the highlights of the exhibition was the official global launch ceremony for the FDA-cleared MQ-8000/MQ-8000PT and MQ-3000/MQ-3000PT HbA1c Analysis Systems.
Mr. Chen Jinlei, Director of International Business at Medconn, joined global partners in witnessing this important milestone.
FDA clearance represents rigorous recognition of product quality and safety, while also demonstrating Medconn's ability to align its core technologies and quality systems with international regulatory requirements. Powered by proprietary algorithms and advanced testing solutions, Medconn's systems provide accurate identification of hemoglobin variants, helping enhance the clinical reliability of HbA1c testing.
This achievement marks an important step forward for Chinese IVD innovation—not simply as a participant in the global market, but as a technology-driven contributor to the evolving international diagnostics landscape.
With this milestone, Medconn is advancing its global presence and developing higher-value diagnostic solutions to support chronic disease management worldwide.
From Proven Technologies to New Breakthroughs
In addition to its FDA-cleared products, Medconn showcased a broad portfolio of core diagnostic solutions designed to address diverse clinical needs.
The next-generation VISTA HbA1c Analysis Platform made its debut, offering faster testing and enhanced hemoglobin variant identification to support diabetes management across the patient journey.
The Medconn Honeycomb Automation Line demonstrated the automation and standardization of HbA1c testing workflows, while the Fully Automated Coagulation Analyzer and next-generation Hematology Analyzer further expanded Medconn's capabilities across the clinical laboratory diagnostics field.
From chronic disease management and hematology screening to standalone instruments and integrated laboratory solutions, Medconn continues to respond to clinical needs through technological innovation, demonstrating the growing capabilities and potential of China's high-end IVD industry.
A Brand with Purpose — The Honeycomb Meets Human-Centered Design
At CACLP 2026, Medconn also introduced an upgraded brand experience through its distinctive “Honeycomb” booth design.
Inspired by efficient collaboration and continuous innovation, the honeycomb structure also represents Medconn's vision of building a connected global network of partners.
The booth attracted strong visitor engagement throughout the exhibition. Interactive ball-toss activities conveyed the product philosophy of “Precision Is Strength,” while the wellness tea area reflected Medconn's human-centered approach. Customized gifts and engaging activities created a more approachable and memorable brand experience.
The “Little Bee” mascot also made an appearance, embodying Medconn's brand values of diligence, focus, and long-term commitment.
From technological breakthroughs and spatial design to product capabilities and human connection, Medconn continues to shape a more multidimensional image of an international healthcare company with a human touch.
